|

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

RECRUITINGSponsored by Chinese Pulmonary Vascular Disease Research Group
Actively Recruiting
SponsorChinese Pulmonary Vascular Disease Research Group
Started2022-06-01
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05566002

Summary

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years old
* Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China

Exclusion Criteria:

* Patients without RHC
* The quality of routine examinations and RHC cannot meet the requirement for further analysis
* Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)

Conditions3

Heart DiseasePulmonary Arterial HypertensionPulmonary Hypertension

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.